開拓藥業-B：年報 2023

Futu News12:11 · Announcements

Cornerstone Pharmaceutical-B (02616.HK): CEO and Executive Director Yang Jianxin purchased 3.345 million additional shares of the company, with a total purchase of 7,529,500 shares

Gelonghui, April 29 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, R&D President and Executive Director, that it purchased a total of 3.345 million shares on the open market with its own capital about six months before the announcement date. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 7,529,500 shares. The purchase price range is HKD0.82 to HKD4.60. After the share purchase, Yang Jianxin held a total of about 4.97% of the company's total issued share capital at the date of the announcement.

Gelonghui Finance12:06

聖諾醫藥-B：2023年度報告

Futu News12:01 · Announcements

Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points

Keymed Biosciences (HKG:2162) said their Class 1 innovative drug CM310 for treating seasonal allergic rhinitis achieved its primary endpoints in a Phase III clinical study, according to a Sunday filin

MT Newswires10:40

April 26 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.74,141 million

According to HKEx's April 29 disclosure documents, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 26, involving an amount of HK$6,1714,400. The repurchase price per share ranged from HK$103.3 to HK$102.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) was 6.314 million shares, accounting for 0.33% of the number of shares issued when the ordinary resolution was passed. ② $too

Futu News09:30

Keji Pharmaceutical-B (02171.HK): Submission of a rectification report on FDA findings

Gelonghui, April 29 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The rectification report on the Corrective and Preventive Measures (CAPAs) plan has been submitted to the US Food and Drug Administration (FDA). This submission relates to findings in Form 483 issued by the FDA after an inspection of the clinical production site in Tulham, North Carolina in December 2023. The relevant work is progressing smoothly according to the schedule previously submitted. The company promises to work closely with the FDA to prioritize quality and ensure the production of clinical trial products.

Gelonghui Finance08:07